why choose us

300×250 Ad Slot

Drug FDA Status

Showing 140 of 185 result(s) (Page 14 of 19)
Drug Name: Wainua

Active Ingredient: eplontersen

Approval Date: 2023-12-21

Description: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Drug Trials Snapshot

Drug Name: Filsuvez

Active Ingredient: birch triterpenes

Approval Date: 2023-12-18

Description: To treat wounds associated with dystrophic and junctional epidermolysis bullosa

Drug Name: Fabhalta

Active Ingredient: iptacopan

Approval Date: 2023-12-05

Description: To treat paroxysmal nocturnal hemoglobinuria

Drug Name: Ogsiveo

Active Ingredient: nirogacestat

Approval Date: 2023-11-27

Description: To treat adults with progressing desmoid tumors who require systemic treatment

Drug Name: Truqap

Active Ingredient: capivasertib

Approval Date: 2023-11-16

Description: To treat breast cancer that meets certain disease criteria

Drug Name: Ryzneuta

Active Ingredient: efbemalenograstim alfa-vuxw

Approval Date: 2023-11-16

Description: To treat neutropenia
Drug Trials Snapshot

Drug Name: Augtyro

Active Ingredient: repotrectinib

Approval Date: 2023-11-15

Description: To treat ROS1-positive non-small cell lung cancer

Drug Name: Defencath

Active Ingredient: taurolidine, heparin

Approval Date: 2023-11-15

Description: To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter

Drug Name: Fruzaqla

Active Ingredient: fruquintinib

Approval Date: 2023-11-08

Description: To treat refractory, metastatic colorectal cancer

Drug Name: Loqtorzi

Active Ingredient: toripalimab-tpzi

Approval Date: 2023-10-27

Description: To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies

300×250 Ad Slot